Evrysdi (risdiplam) is an oral liquid treatment approved in the U.S. for infants through adults with spinal muscular atrophy (SMA) — patients age 2 months and older with any disease type. Roche and Genentech developed Evrysdi in collaboration with PTC Therapeutics and the SMA…
FAQs
Spinal muscular atrophy (SMA) is a rare genetic disease with several subtypes. Patients and their caregivers may have a difficult time finding reliable information about SMA, so here are some frequently asked questions and answers about the disease: What is SMA? SMA is a neurodegenerative disease characterized by the…
